AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shike, M.
Right arrow Articles by Flombaum, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shike, M.
Right arrow Articles by Flombaum, C.
Agricola
Right arrow Articles by Shike, M.
Right arrow Articles by Flombaum, C.

American Journal of Clinical Nutrition, Vol 44, 89-98, Copyright © 1986 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Bone disease in prolonged parenteral nutrition: osteopenia without mineralization defect

M Shike, ME Shils, A Heller, N Alcock, V Vigorita, R Brockman, MF Holick, J Lane and C Flombaum

A metabolic bone disease characterized by a mineralization defect, low plasma 1,25(OH)2D, and hypercalciuria has been described in patients receiving prolonged total parenteral nutrition (TPN). Because the practice of TPN differs from center to center, we investigated 13 home TPN patients to determine whether they had similar or different bone abnormalities. They had received TPN for a mean period of 51 +/- 38 mo. Bone pain occurred in six patients and two had multiple vertebral and rib fractures (with trauma in one patient). Bone pain was mild to moderate and not incapacitating. Bone histomorphometry showed reduced bone volume, reduced osteoid with normal resorption and calcification rates. These abnormalities were associated with hypercalciuria, but the plasma levels of 1,25(OH)2D were normal. Abnormalities in bone metabolism in this group of patients suggest a fundamental decrease in bone matrix-formation rather than a mineralization defect as the underlying mechanism.


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
M. Ferrone and M. Geraci
A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease
Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
M. Pazianas, C. Compher, P. Schiavone-Gatto, and B. P. Kinosian
Intestinal Failure-Associated Metabolic Bone Diseases and Response to Teriparatide
Nutr Clin Pract, December 1, 2006; 21(6): 605 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
K. V Haderslev, L. Tjellesen, H. A Sorensen, and M. Staun
Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition
Am. J. Clinical Nutrition, August 1, 2002; 76(2): 482 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
W. G Goodman, S. Misra, J. D Veldhuis, A. A Portale, H.-J. Wang, M. E Ament, and I. B Salusky
Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition1
Am. J. Clinical Nutrition, February 1, 2000; 71(2): 560 - 568.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by The American Society for Nutrition